Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ON Holding AG — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while ON Holding AG trades at $38.61 (market cap $12.85B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× ON Holding AG's market cap, and ON Holding AG is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ONON | |
|---|---|---|
Market Cap | $39.89B | $12.85B |
Sector | Health | Technology |
52-Week High | $491.22 | $54.24 |
52-Week Low | $278.09 | $31.88 |
Enterprise Value | $38.15B | $12.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ONON trades at $38.54, up 4.81% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 63.88% gross margins and 15.5% ROE. Analyst sentiment is overwhelmingly positive with a $47.33 consensus target, though technical indicators suggest near-term resistance at $39.
Outlook remains favorable given consistent earnings outperformance and margin expansion, but elevated valuation multiples and bearish technical trends present near-term risks. The primary opportunity lies in continued execution against growth targets, while risks include market volatility and competitive pressures in the athletic apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
